2022
Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota
Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics 2022, 11: 324. PMID: 35326788, PMCID: PMC8944611, DOI: 10.3390/antibiotics11030324.Peer-Reviewed Original ResearchMinimum inhibitory concentrationVitro minimum inhibitory concentrationHigh minimum inhibitory concentrationsTetracycline-class antibioticsTime-kill assaysBroad-spectrum tetracycline antibioticTime-kill kinetic assayGastrointestinal tract microbiotaHigh MIC valuesHuman gastrointestinal microbiotaLess activityAcne treatmentGut microbiotaMinocyclineGut microbiomeGastrointestinal microbiotaSarecyclineInhibitory concentrationGut microorganismsSkin microbiomeVivo testingReduced activityMicrobiotaMIC valuesAntibiotics
2021
Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation
Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics 2021, 10: 439. PMID: 33920812, PMCID: PMC8071131, DOI: 10.3390/antibiotics10040439.Peer-Reviewed Original ResearchTetracycline-class antibioticsBroad-spectrum antibiotic useRat paw edema modelPaw edema modelAnti-inflammatory activityWound infection modelSevere acneEdema modelPatient outcomesAntibiotic useMurine modelAnimal modelsDrug AdministrationGut microfloraInfection modelSarecyclineVivo studiesRelevant Gram-positive bacteriaReduced efficacyInfectionAntimicrobial resistanceVivo activityAntibiotic resistanceInflammationReduced activity